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Abstract: Background: Tanzania HIV/AIDS management follows WHO clinical staging which requires CD4 counts as 
complement. Lacking CD4 counts facilities in rural health facilities remains a challenge. Simplified and sensitive clinical 
staging based on local clinical patterns is useful to ensure effective care without CD4 counts. 
Objectives: To assess whether local HIV clinical manifestations can be used to guide HIV management in settings with 
limited access to CD4 counts in Tanzania.  
Methods: A Cross-sectional study conducted at Tumbi and Chalinze health facilities documented clinical manifestations 
and CD4 counts in 360 HIV/AIDS patients. Simplified management groups comprised of severe and moderate disease 
were formed based on clinical manifestations and CD4 counts results. Symptoms with high frequency were used to 
predict severe disease. 
Results: Weight loss (48.3%) and chronic cough (40.8 %) were the most reported manifestations in the study population. 
More than 50% of patients presented with CD4200. Most symptoms were found to be highly sensitive (71% to 93%) in 
predicting severe immunosuppression using CD4<200 cut-off point as a ‘Gold standard’. Chronic diarrhoea presented in 
10.6%, and predicted well severe immunosuppression either alone (OR 1.95, 95%CI, 0.95-4.22) or in combination (OR 
4.21, 95%CI 0.92-19.33) with other symptoms. Basing strictly on WHO clinical staging 30.8% of patients were detected 
to be severely immunosuppressed (Stage 4). While using our proposed management categories of severe and moderate 
immunosuppression 70% of patients were put into the severe immunosuppression group, consistent with CD4 cut-off 
count of350. 
Conclusions: HIV/AIDS clinics managing large cohorts should develop validated site specific guidelines based on local 
experiences. Simplified guidelines are useful for resource constrained settings without CD4 counting facilities.  
Keywords: HIV, AIDS, clinical manifestation, staging, peripheral, Tanzania. 
INTRODUCTION 
  In sub-Saharan Africa, the transmission of Human 
Immunodeficiency Virus (HIV-1) occurs mostly through 
heterosexual contact and the progression to Acquired 
Immunodeficiency Syndrome (AIDS) and premature death is 
the reality for people in most poor areas with limited access 
to Antiretroviral Therapy (ART) [1-3]. HIV disease 
progresses from an asymptomatic period of variable   
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duration, through mild symptoms, to severe disease 
characteristic of cellular immunodeficiency [1].  
  Human Immunodeficiency Virus clinical presentation is 
known to be complex since AIDS was described in 1981[2, 
3]. HIV can manifest in a variety of ways depending on the 
organs affected and concurrent infections prevalent in the 
area. The initial clinical presentation may mimic symptoms 
of common endemic diseases in that particular region [4, 5] 
However, the severity of manifestation depends on the 
infected individual’s baseline health status. The most 
significant early manifestation of HIV infection in Africa 
was marked by slim disease (diarrhoea and wasting); 
tuberculosis; variety of Opportunistic Infections (OI); weight 
loss, fever; and dermatological symptoms [2,5,6]. With the 10    The Open AIDS Journal, 2011, Volume 5  Boniphace et al. 
exception of tuberculosis which continues to increase, other 
AIDS related diseases are declining gradually due to the 
widespread use of OI drugs. 
  World Health Organization (WHO) has established a four 
stage clinical classification system determined by the 
presence of Opportunistic Infections and other HIV related 
conditions [7]. This classification tried to incorporate most 
of the AIDS-defining illnesses occurring in all regions of the 
world making a global tool for HIV/AIDS patients care and 
treatment. It has been a very useful tool in Sub Saharan 
Africa at the introduction of antiretroviral drugs and 
establishment of HIV/AIDS treatment cohorts
 [8]. It helped 
to capture rapid deteriorating patients and initiation of ART 
in settings with limited diagnostic resources and less trained 
clinicians.  
  Antiretroviral drugs are widely available nowadays and 
continue to be scaled up in remote rural areas of sub Saharan 
Africa [9, 10]. The aim of rapid scale up is to reach more 
people living with HIV and AIDS who cannot easily access 
ART services in urban hospitals. The main challenges to this 
plausible strategy include availability of qualified health 
workers and laboratory services to ensure quality care and 
the monitoring of drug use [11-13]. In addition, most 
patients including HIV-infected patients in Sub Saharan 
Africa present late for hospital care and treatment when the 
disease has advanced [13-15]. By then initial AIDS signs and 
symptoms might have been treated empirically through self 
medication or use of herbal medicines. Such remedial 
actions usually obscure important AIDS clinical features and 
make it difficult for the attending clinician to solicit signs 
and symptoms to properly stage the patient.  
  It is evident that HIV/AIDS patients’ management in Sub 
Saharan Africa continues to be guided primarily by clinical 
staging
  [8, 16, 17] owing to the insufficient availability 
and/or frequent breakdowns of CD4 cells count machines, 
shortage of qualified medical personnel and laboratory 
reagents and other logistic issues impair [18]. On the other 
hand WHO clinical staging depends on a patient presenting 
signs and symptoms; knowledge and skills of the health care 
worker to make a definitive staging [8,17,19]. Furthermore, 
WHO clinical staging is less sensitive in identifying patients 
with CD4 cell counts between 200 -350 cells per L [4, 20]. 
Therefore, it fails to identify some patients in need of ART.  
  Taking into considerations the complexities of HIV 
clinical manifestation in our setting which often does not 
match WHO clinical staging. Clinicians in lower health 
facilities, who are expected to attend to HIV patients in their 
local settings, need simplified and easy to use clinical 
staging guidelines developed by utilizing site specific data 
and clinical experiences. This approach could effectively 
support management of HIV/AIDS patients in ART cohorts 
based on site specific experiences. Moreover, the broader 
availability of ART as well as new approaches to deal with 
opportunistic infections call for a review of the clinical 
presentations seen within care and treatment programs in 
different settings. To date, no studies have proposed 
simplified HIV/AIDS clinical staging based on local 
experience. With the inspiration of WHO validated 
HIV/AIDS clinical definition, our study aimed at developing 
simplified HIV/AIDS clinical staging system based on data 
 
Fig. (1). Patients profile flow chart. 
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generated locally from peri-urban and rural health facilities 
to allow more effective patient management and ART 
cohorts at peripheral level in the absence of CD4 counts.  
METHODS 
Setting and Study Participants 
  The study was conducted at Tumbi Regional Hospital 
and Chalinze Health Centre in Pwani Region, Eastern 
Tanzania between April and December 2008. Tumbi 
Regional Hospital is located 40 km from Dar es Salaam, the 
commercial capital of Tanzania. The hospital has a bed 
capacity of 200 beds and serves as a regional referral 
Hospital. Chalinze Health Centre is located 70 km from 
Tumbi Hospital at the junction of the main upcountry 
highways with HIV prevalence of 15%, while Pwani Region 
prevalence was 7%. Both health facilities provide services to 
a mixture of patients from urban and rural villages. Most 
residents of Chalinze reside in rural villages and generate 
income from farming and trading of different types of goods. 
  Tumbi Hospital runs two separate HIV/AIDS clinics for 
adults and children. At the time of initiation of this study in 
April 2008, Tumbi Hospital and Chalinze Health Centre had 
enrolled a total of 3851 and 450 patients to care and 
treatment, respectively.  
  We recruited HIV-infected adult patients (age 15 years) 
coming for the first time to register for care and treatment 
services. The inclusion criteria included; permanent 
residence to the health facility catchments area; no prior use 
of ARVs and or co-trimoxazole prophylaxis. A total of 360 
female and male patients consented to participate in the 
study as depicted in the flow chart (Fig. 1). Recruitment of 
study participants lasted for 3 months. 
Data Collection 
  Each consenting patient was clinically examined in the 
standard way that involved a detailed history, physical 
examination and laboratory tests. Additional laboratory tests 
depended on the suspected diagnosis. Patients’ socio-
demographic characteristics and clinical information were 
recorded in a structured report form in addition to routine 
patient case report forms.  
Laboratory Procedures 
  Blood, sputum, urine and stool samples were collected 
and analyzed. Blood samples were analyzed for CD4 cell 
counts, HIV-1 P24 plasma ELISA assay, haemoglobin, liver 
and renal function tests. Blood was collected in EDTA tubes 
for enumeration of CD4 cells by using FACS count (BD 
Biosciences, California, USA). Biochemistry and haematolo-
gical parameters were analyzed using Biochemical analyzer 
(Italy) and haematological analyzer (Pentra 80, France) 
respectively. Thick blood smears were Giemsa stained and 
microscopically examined for Malaria parasitaemia [21]. 
Sputum specimens were stained using Ziehl-Neelsen 
technique and examined for mycobacterium tuberculosis 
[22]. 
  Stool samples were fixed using sodium acetate-acetic 
acid-formalin (SAF) solution and microscopically examined 
for intestinal parasites. Part of freshly passed stool was 
inoculated and cultured in Xylose Lysine Deoxycholate Agar 
(XLD) media for Salmonella and Shigella species. A direct 
microscopic examination was performed on urine samples. 
This paper focuses on CD4 cell counts results in comparison 
to the WHO clinical staging. 
Data Analysis 
  All data was entered into Microsoft 
®Access, and 
analyzed using Stata Intercooled version 9.  
  Each clinical symptom or sign was coded and counted 
individually to estimate the frequency of occurrences from 
every patient. About 140 different signs and symptoms were 
recorded. Then the frequencies were used to estimate the 
proportion of patients with that particular sign or symptom. 
Only signs and symptoms with high frequencies were used 
in this analysis.  
  We attempted to form two simplified management 
groups of patients based on either CD4 counts categories or 
WHO clinical stages. With respect to WHO clinical staging; 
group one (severe immune suppression) is formed by 
patients with clinical stages III/IV and group two (moderate 
immune suppression) is formed by patients with clinical 
stages I/II. Similarly, when using CD4 cell counts severe 
immune suppression was defined by patients with CD4200 
cells per L whilst moderate immune suppression is formed 
by patients with CD4>200 cells per L.  
  We then determined sensitivity, specificity, positive and 
negative predictive values using CD4 cells count level as the 
“gold standard”. Symptoms or signs individually and in 
combinations were used to predict severe disease. Only 
symptoms which had high frequency and troubled the patient 
for more than two weeks were used.  
Ethical Approval 
  The study received scientific and ethical approval from 
the Muhimbili University of Health and Allied Sciences 
Research Ethics Review Board. Permission was obtained 
from Region, District and local site authorities. Written 
informed consent or witnessed verbal consent for 
participants unable to read or write was obtained from each 
patient in Kiswahili. 
RESULTS 
  During the study period 421 HIV-infected patients aged 
15 to 80 years were recruited to participate in the study, 
341(81.0%) and 80(19.0%) were from Tumbi hospital and 
Chalinze health centre, respectively. Sixty one (14.5%) 
patients declined to participate due to various reasons (Fig. 
1). In total 360(85.5%) patients were consented, complete 
data for analysis was recorded from 331 (78.6%) patients. 
Twenty nine patients were excluded from the final analysis 
due to incomplete data, i.e. doubtful CD4 counts results or 
names, age and sex not corresponding to clinical 
information. Patients rejected to participate in the study and 
those excluded from analysis had similar social and 
demographic characteristics to those finally analyzed. 
Socio-Demographic and Clinical Characteristics 
 Table  1 summarizes demographic and clinical 
characteristics of the participants. There were 191(57.7%) 
patients in the study with CD4+ T-lymphocytes count of less 
than 200 cells per L. The median age was comparable in 12    The Open AIDS Journal, 2011, Volume 5  Boniphace et al. 
both groups of patients with mild and severe 
immunosuppression. Most patients 214(64.7%) were 
females, and the majority 223(67.4%) of patients resided in 
rural areas. Seventeen patients (8.9%) and 37(19.4%) with 
CD4+ T-lymphocytes below 200 cells per L were classified 
with WHO clinical stages I and II, respectively. Similarly, 
35(25.0%) and 25(17.9%) of patients were staged in clinical 
stages III and IV, respectively, had CD4+ T-lymphocytes 
greater than 200 cells per L. The overall median CD4+ T-
lymphocytes counts at enrolment was 158(IQR 253) cells per 
L, with the lowest median (77.5 (IQR 99.5)) in patients 
with severe immunosuppression. 
Patient’s Main Presenting Symptoms and Signs at 
Recruitment 
  At presentation to the clinic weight loss of more than 5 
kg was the most frequent 160(48.3%), followed by chronic 
cough that persisted for more than 2 weeks 135(40.8 %). 
Diarrhoea was less common (10.6 %) in this study 
population. Recurrent fever was recorded in 132(39.9%) 
patients; other symptoms with high frequency included 
headache 105(31.7 %); Peripheral neuropathy 57(17.2%) and 
dizziness 70(21.1%). Various types of skin diseases were 
recorded in 34(10.3%) patients, but Pruritic Papular 
Eruptions was the most common dermatological condition 
(Table 2A). Thirty six (11%) patients presented with genital 
discharge; 12(33%) of them had sexually transmitted 
infections. In addition to major clinical symptoms and signs; 
132 (37%) patients presented with mild non-specific various 
clinical features. Major AIDS-defining Opportunistic 
Infections diagnosed in this study included: Tuberculosis 
(15%); Pneumocystis carinii Pneumonia (7%); Herpes zoster 
(5%); Cryptococcus meningitis (3%); and Kaposi’s sarcoma 
(3%).  
Table  1.    Demographic and Clinical Characteristics of Patients at First Clinical Assessment Grouped by CD4 Cell Count 
Categories  
 
Variable  All Patients (N=331)  CD4>200 Cells per L 
(N=140) 
CD4200 Cells per L 
(N=191) 
p-Value 
Median age in years(IQR)   36(12)  36 (14)  36 (10)   
Sex N (%) 
Male 
Female 
 
117(35.3) 
214(64.7) 
 
49 (35.0) 
91 (65.0) 
 
68 (35.6) 
123 (64.4) 
 
P=0.910 
 
Residential status N (%) 
Urban 
Rural 
 
108(32.6) 
223(67.4) 
 
47 (33.6) 
93 (66.4) 
 
61 (31.9) 
130 (68.1) 
 
P=0.754 
WHO Clinical stage N (%) 
I 
II 
III 
IV  
 
59(17.8) 
75(22.7) 
95(28.7) 
102(30.8) 
 
42 (30.0) 
38 (27.1) 
35 (25.0) 
25 (17.9) 
 
17 (8.9) 
37 (19.4) 
60 (31.4) 
77 (40.3) 
 
P=0.0001 
Median CD4+ T- cells per L (IQR)  158(253)  377 (259)  77.5 (99.5)   
Table  2A.   Symptoms and Signs for HIV/AIDS Persisting for More than Two Weeks and their Performance to Predict severe 
Immunosuppression at First Assessment (P-value  0.25) 
 
CD4200 Cells per L  WHO Clinical Stage 
III /IV 
Symptom/Sign 
Frequency of 
Signs and 
Symptoms N 
(%)  Odds Ratio  CI 
Odds 
Ratio  CI 
Sensitivity 
(%) 
Specificity 
(%) 
Weight loss >5kg  160 (48.3)  1.39  0.89-2.16  2.49  1.58-3.95  81  46 
Cough   135 (40.8)  1.44  0.92-2.25  3.28  2.02-5.32  82  36 
Fever 132  (39.9)  1.67  1.06-2.63  2.74  1.70-4.41  83  43 
Headache 105  (31.7)  0.96  0.60-1.54  1.22  0.76-1.97  80  60 
Dizziness 70  (21.1)  1.53  0.88-2.65  1.93  1.06-3.43  80  46 
Peripheral neuropathy  57 (17.2)  1.00  0.56-1.79  1.44  0.79-2.63  85  58 
Diarrhoea 35  (10.6)  1.95  0.95-4.22  1.55  0.73-3.28  84  70 
Skin diseases  34 (10.3)  1.20  0.58-2.50  1.27  0.60-2.67  71  46 
Fungal infection (skin and mucous membranes)   24 (7.3)  1.24  0.52-2.92  2.75  1.00-7.56  93  44 HIV/AIDS Clinical Manifestations and their Implication  The Open AIDS Journal, 2011, Volume 5    13 
  Performance of clinical features to predict severe 
immunosuppression in comparison to WHO clinical   staging  
Tables 2A, 2B and 2C demonstrate the performance of each 
AIDS presenting symptom alone or in combination with 
other symptoms in predicting severe immunosuppression. 
Patients presenting with diarrhoea for more than two weeks 
have about double the odds ratio of being severely 
immunosuppressed. Diarrhoea is an important predictor of 
severe immunosuppression even when presenting with other 
symptoms (odds ratio ranging from 1.97(95%CI, 0.68-5.66) 
to 4.21(0.92-19.33) for two and three combination of 
symptoms). Chronic cough and weight loss are routinely 
used to classify patients in stages III and IV (WHO odds 
ratio of 3.28 (95%CI, 2.02-5.32), 2.49(1.58-3.95) 
respectively), but do not specifically predict severe 
immunosuppression (CD4200 odds ratios 1.44(95%CI, 
0.92-2.25) and 1.39(95%CI, 0.89-2.16), respectively) when 
presented as individual symptoms. Their performance in 
predicting severe immunosuppression improves when 
presented in combination with other HIV/AIDS clinical 
manifestations (Tables 2B and 2C).  
  Headache, Dizziness and Peripheral neuropathy were 
among the most frequent symptoms. These symptoms appear 
to be highly sensitive (sensitivity 80-85%) in predicting 
severe immunosuppression when used as individual 
symptoms. Similarly, HIV/AIDS patients presenting with 
dizziness have about two times the odds of being staged in 
WHO clinical stage III/IV (WHO odds ratio=1.93(95%CI, 
1.06-3.43)). But these are non- specific HIV/AIDS clinical 
manifestations and poorly predicted severe immuno-
suppression when compared to CD4 cell counts (CD4200 
odds ratios 0.96(95%CI, 0.60-1.54) and 1.53(95%CI, 0.88-
2.65) respectively). The same symptoms when presented in 
combination with other symptoms such as diarrhoea the 
probability of predicting severe immunosuppression 
increases (CD4200 odds ratio 4.21(95%CI, 0.91-19.33) for 
the combination of dizziness and diarrhoea; and for weight 
loss, headache and diarrhoea). 
  Sensitivity of each one or combination of two most 
frequent symptoms to predict severe disease was between 
71% (Skin disease) and 93% (Fungal infection); and 
specificity minimum 29% (combination of cough and fever) 
and maximum 70% (Diarrhoea). Fungal infection carried the 
highest sensitivity of 93% with WHO clinical stage III/IV 
odds ratio of 2.75(1.0-7.56). But, when compared to CD4 
cell counts, the CD4 200 odds ratio drops to 1.24(0.52-
2.92). 
  The combinations of three clinical features resulted in an 
improved prediction of severe immune suppression. 
However, adding headache into a combination fever and 
diarrhoea increased the odds of severe immunosuppression 
(based on CD4 counts) from 2 to 4 folds. A similar trend is 
observed when added in a combination of weight loss and 
Table 2B.  Performance of a Combination of Two Clinical Features in Predicting Severe Immunosuppression (P-value  0.25) 
 
CD4200 Cells per L 
 
WHO Clinical Stages 
III /IV 
 
Symptom/Signs  
Combinations 
 
Frequency of Signs 
and Symptoms N 
(%) 
Odds Ratio  CI  Odds Ratio  CI 
 
Sensitivity 
(%) 
 
Specificity 
(%) 
Cough and fever  74 (22.4)  1.71  0.99-2.95  3.39  1.82-6.28  84  29 
Weight loss and cough  84 (25.4)  1.78  1.06-2.99  3.79  2.11-6.81  86  32 
Cough and Diarrhoea  18 (5.4)  1.97  0.68-5.66  2.48  0.8-7.72  92  60 
Weight loss and fever  96 (29.0)  1.40  0.86-2.29  2.64  1.55-4.47  85  43 
Fever and diarrhoea  24 (7.3)  2.32  0.89-6.01  2.14  0.82-5.55  83  50 
Weight loss and diarrhoea  24 (7.3)  1.85  0.74-4.60  2.14  0.82-5.55  88  57 
Dizziness and diarrhoea  13 (3.9)  4.21  0.91-19.33  3.90  0.85-17.90  85  43 
 
Table 2C.  Performance of a Combination of Three Clinical Features in Predicting Severe Immunosuppression (P-value  0.25) 
 
CD4200 Cells per L  WHO Clinical Stage III/IV 
 
Symptom/Signs  
Combinations 
 
Frequency of 
Symptoms and 
Signs N (%)  Odds Ratio  CI  Odds Ratio  CI 
Cough, fever, Weight loss>5kg  61(18.4)  1.79  0.99 -3.25  3.80  1.89 - 7.62 
Cough, diarrhoea,  difficult breathing  10 (3.0)  3.01  0.63 - 14.42  6.36  0.79 - 50.85 
Fever, headache, diarrhoea  13(3.9)  4.21  0.92 - 19.33  3.90  0.85 - 17.90 
Fever, diarrhoea,  Difficult breathing  12(3.6)  2.25  0.60 - 8.49  3.52  0.763 - 16.37 
Weight loss>5kg, headache, diarrhoea  13(3.9)  4.21  0.92 - 19.33  3.90  0.85 - 17.90 
Weight loss>5kg, Difficult breathing poor appetite  38(11.5)  1.68  0.82 - 3.45  5.19  1.97 - 13.67 
Abdominal pain, Headache, diarrhoea  13(3.9)  2.52  0.68 - 9.34  2.33  0.63 - 8.64 
Headache, Difficult breathing, poor appetite  21(6.3)  1.90  0.72 - 5.03  3.06  1.00 - 9.33 14    The Open AIDS Journal, 2011, Volume 5  Boniphace et al. 
diarrhoea contrary to difficulty in breathing which behaved 
differently when added in a combination of cough and 
diarrhoea and or fever and diarrhoea.  
DISCUSSION 
  This study attempted to develop and validate HIV 
clinical staging tailored to a particular geographical and 
endemic area in comparison to the well established WHO-
staging. The clinical profiles of about 34% of patients were 
unique and obscured which in turn resulted in WHO staging 
that was inconsistent with the CD4 cell counts. The majority 
of the patients presented with clinical features of weight loss 
(and wasting); chronic cough; and persistent fever for more 
than 2 weeks. These are common symptoms and signs which 
were described as early HIV manifestation and significantly 
were associated with sero-conversion in the first decades of 
HIV epidemic [23, 24]. We also observed a marked shift in 
AIDS clinical manifestation from the classical AIDS clinical 
manifestations [23] which previously was marked by 
profound weight loss of more than 10% body weight; 
chronic diarrhoea and prolonged fever for more than one 
month to a mixed picture of signs and symptoms [23-25]. 
Although, our patients had reported weight loss, the weight 
loss was limited to more than 5 kg and less than 5% (data not 
shown) of their initial body weight. The clinical spectrum 
seen among the patients in both study sites are quite 
representative to the overall clinical pictures of the 
HIV/AIDS patients in the area. The two sites are the only 
care and treatment centres in the whole area. 
  Interestingly, only 10.6% of the patients presented with 
chronic diarrhoea. This is a marked reduction in occurrence 
of diarrhoea among HIV/AIDS patients attending care and 
treatment clinics. Diarrhoea is well known to affect 40%-
80% HIV infected persons and was also associated with high 
mortality rates in Sub-Saharan Africa [24, 26, 27]. The 
reduction in prevalence of diarrhoea in HIV infected people 
can be explained by the now broader availability of OIs 
drugs and co-trimoxazole without prescription. 
  Working at care and treatment centres, we recruited 
newly diagnosed HIV patients that were all included in the 
ART cohorts according to the Tanzania National HIV/AIDS 
control programme guidelines. We expected to record more 
pre-AIDS signs and symptoms such as generalized 
lymphadenopathy, Herpes zoster and mucocutaneous 
lesions. Instead, one third of our patients presented with 
minor non specific and often no symptoms. Most of these 
patients had CD4 cell counts less than 200 cells per L. 
Herpes zoster was diagnosed in 5% of patients, most of them 
had CD4 cell counts below 200 cells per L which is 
contrary to the common believe that Herpes zoster is a stage 
II disease. It is a reality in most rural, poor communities to 
accept a HIV test after suffering for a long time and tried on 
all kinds of remedies without success. During this time their 
CD4 cell counts progressively declined. 
  Most of the known common HIV related opportunistic 
infections were less frequent than expected in this population 
despite many patients having CD4 cell counts less than 200 
cells per L. It is well established that patients at this level of 
CD4 cell counts have high risk of AIDS opportunistic 
infections and AIDS related cancers [28]. Tuberculosis was 
diagnosed in only 15% of the patients despite the high 
frequency of chronic cough and difficulty in breathing. 
Patients with extra pulmonary tuberculosis and Pneumocystis 
carinii pneumonia could be missed due to limited respective 
diagnostic facilities. The diagnosis of these diseases was 
based on sputum and chest x-ray findings. In routine 
practice, tuberculosis in HIV-infected patients requires 
regular screening at every visit because single screening does 
not exclude latent infection that can flare up in the course of 
HIV disease progression.  
 Cryptococcus  meningitis and Kaposi’s sarcoma were 
diagnosed in only 3% of the patients. However, the lower 
rate of HIV related cancers can be justified by the small 
sample size of this study. Overall, the different clinical 
patterns and frequencies of opportunistic infections may 
largely be due to changed approaches in the clinical 
management brought forward by (i) the broader availability 
of ART in combination with the establishment of care and 
treatment centres as part of the Tanzania National HIV/AIDS 
control program and (ii) the new approaches to handle 
prophylactically and therapeutically opportunistic infections 
also outside the Tanzania National HIV/AIDS control 
program.  
  The level of incorrect WHO clinical staging found in this 
study is almost similar to Ugandan experiences where about 
50% of patients were inappropriately staged [20]. In routine 
clinical practice WHO clinical stages determine the direction 
of HIV/AIDS case management. Patients in clinical stages I 
and II usually receive long time appointments accompanied 
by minimum laboratory investigations. While, patients in 
clinical stages III and IV usually receive clinical and 
laboratory assessment to determine their eligibility to start 
ART. Therefore, when a sizable proportion of patients 
cannot be staged correctly at first contact in ART clinics, the 
initiation of ART is delayed and higher mortality rates can 
be expected in the first three months of ART [13].  
  More than half of our patients were in WHO clinical 
stages III and IV which was consistent to the number of 
patients with CD4 cell counts of less than 200 cells per L. 
This is the reality of late presentation and a challenge to 
ART programs. Using the cut off point for severe 
immunosuppression of CD4 cell counts 200 cells per L; 
comparison is more conservative based on the Tanzania Care 
and Treatment Guidelines [16]. However, if a CD4 cell 
count of 350 cells per L is taken as cut off for advanced 
immune depression, then the proportion of patients with 
severe immune depression reaches about 70% of all cases 
seen in this study. Taking into consideration the high 
proportion of patients presenting late with obscured clinical 
features to care and treatment for the first time, it appears 
advantageous to classify patients into severe and moderate 
immune-suppression. Such an approach simplifies the 
process of clinical staging and reduces the chances of missed 
appropriate staging and hence delays in starting ART can be 
avoided.  
  In our study, skin diseases and fungal infections of the 
skin and mucous membranes indicated severe immuno-
suppression when used clinically to stage patients. However, 
these symptoms do not strongly predict severe 
immunodeficiency based on CD4 decline (odds ratio 1.2, 
95%CI, 0.52-2.92). In addition about 75% of patients with 
herpes zoster were severely immunosuppressed. Most of the HIV/AIDS Clinical Manifestations and their Implication  The Open AIDS Journal, 2011, Volume 5    15 
symptoms showed high sensitivity in predicting severe 
immunosuppression which is also an indication of clinicians’ 
adherence to treatment guidelines. When compared to CD4 
count levels, there was no consistency. If the combination of 
three clinical features is used, the probability of predicting 
severe disease reaches 100% and is consistent with the 
decline of CD4 cell counts. High sensitivity with lower 
specificity further supports this patients’ classification 
because of the vulnerability of HIV patients to opportunistic 
infections if missed and delayed to receive ART.  
  Based on these study findings, we then recommend for 
the local application of the new classification of HIV 
infected patients into severe and moderate immuno-
suppression based on duration of clinical manifestations. 
This classification guided by local clinical experience - 
requires further validation. We recognize the small sample 
size used in this study as a limitation. However the 
composition of patients from rural and urban settings implies 
that the guidelines established can be used at a regional level. 
Therefore and besides our current own efforts, more studies 
should be conducted to validate the proposed approach of 
staging, not only for patients’ classification but also for 
monitoring drug side effects and treatment failure in other 
geographical and endemic settings. 
CONCLUSION 
  The broader availability of HIV/AIDS treatment as well 
as new approaches to deal with opportunistic infections, we 
call for a review of the clinical presentations seen within care 
and treatment programs in different settings. Besides 
applying the WHO clinical staging care and treatment 
centres that look after large cohorts of HIV and AIDS 
patients information should also be collected to develop and 
validate site specific guidelines based on local experiences as 
shown in this study of which the results are currently being 
validated in other settings.  
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